Capecitabine Accord 300 mg film-coated tablets

DRUG4 trials

Sponsors

Fondation Franc.Cancerologie Digestive, Bristol-Myers Squibb Services Unlimited Company, Centre Hospitalier Universitaire De Dijon, Institut Gustave Roussy

Conditions

Ampullary adenocarcinomaBiliary tract carcinomaPan tumorPancreatic NeuroEndocrine Tumors (PanNET) ; Aggressive stage I-III well differentiated R0 resected

Phase 2

PRODIGE 76-IMMUNOBILADJ: Capecitabine plus durvalumab or capecitabine alone as adjuvant therapy in patients with resected biliary tract carcinoma. A non-comparative randomized phase II study

CompletedCTIS2023-503807-27-00

Fondation Franc.Cancerologie DigestiveBiliary tract carcinoma

End: 2023-08-29Target: 219Updated: 2023-07-07

Pan Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS sponsored Trials Investigating Nivolumab and Other Cancer Therapies

RecruitingCTIS2023-506914-32-00

Bristol-Myers Squibb Services Unlimited CompanyPan tumor

Start: 2020-05-05Target: 307Updated: 2026-01-19

Phase 3

PRODIGE 98- AMPIRINOX : Randomized, multicenter, Phase III trial of adjuvant chemotherapy with modified FOLFIRINOX versus capecitabine or gemcitabine in patients with resected ampullary adenocarcinoma.

RecruitingCTIS2024-511070-68-01

Centre Hospitalier Universitaire De DijonAmpullary adenocarcinoma

Start: 2024-09-24Target: 294Updated: 2025-08-29

First adjuvant trial in locally resected aggressive pancreatic neuroendocrine tumors: a randomized phase III investigating the efficacy of systemic chemotherapy (ADJUPANET)

Not yet recruitingCTIS2025-523593-16-00

Institut Gustave RoussyPancreatic NeuroEndocrine Tumors (PanNET) ; Aggressive stage I-III well differentiated R0 resected

Target: 504Updated: 2026-06-10